Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$15 Mln
Revenue (TTM)
$53 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
269.8
Industry P/E
--
EV/EBITDA
-3.6
Div. Yield
0 %
Debt to Equity
0.9
Book Value
$0.3
EPS
$-0.3
Face value
--
Shares outstanding
16,992,253
CFO
$-29.51 Mln
EBITDA
$-58.96 Mln
Net Profit
$-64.37 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IRIDEX (IRIX)
| -16.7 | -32.2 | -16.7 | -4.1 | -22.4 | -32.4 | -21.1 |
|
BSE Sensex*
| -13.5 | -9.9 | -14.0 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
IRIDEX (IRIX)
| -32.1 | -40.0 | 39.8 | -67.1 | 143.4 | 12.6 | -52.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IRIDEX (IRIX)
|
0.9 | 15.1 | 52.7 | -4.4 | -4.9 | -126.4 | -- | 269.8 |
| 7.8 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.1 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.9 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.6 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 75.7 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.0 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 329.0 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 118.3 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo... G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. Address: 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043 Read more
President, CEO & Director
Mr. David I. Bruce
President, CEO & Director
Mr. David I. Bruce
Headquarters
Mountain View, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of IRIDEX Corporation (IRIX) is $0.95 (NASDAQ) as of 01-Apr-2026 16:11 EDT. IRIDEX Corporation (IRIX) has given a return of -22.37% in the last 3 years.
Since, TTM earnings of IRIDEX Corporation (IRIX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.42
|
3.98
|
|
2024
|
-3.14
|
13.33
|
|
2023
|
-4.77
|
4.79
|
|
2022
|
-4.26
|
1.87
|
|
2021
|
-18.55
|
4.16
|
The 52-week high and low of IRIDEX Corporation (IRIX) are Rs 1.65 and Rs 0.79 as of 02-Apr-2026.
IRIDEX Corporation (IRIX) has a market capitalisation of $ 15 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in IRIDEX Corporation (IRIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.06
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.